Back to Browse Journals » Research and Reports in Endocrine Disorders » Volume 3

An update on the treatment of acromegaly

Authors Edling KL, Heaney AP

Published Date February 2013 Volume 2013:3 Pages 1—11

DOI http://dx.doi.org/10.2147/RRED.S24231

Received 9 August 2012, Accepted 8 October 2012, Published 26 February 2013

Kari L Edling,1 Anthony P Heaney1,2

1Department of Medicine, 2Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Abstract: Acromegaly is caused by pituitary somatotroph hypersecretion of growth hormone leading to elevated hepatic-derived and local levels of insulin-like growth factor-1. It is associated with increased morbidity and mortality due primarily to cardiovascular disease and diabetes mellitus. Normalization of growth hormone and insulin-like growth factor-1 levels has been associated with decreased morbidity from metabolic and cardiovascular effects, as well as reduced overall mortality in epidemiologic studies. Many patients experience a delay in obtaining a diagnosis, have pituitary macroadenomas at presentation, and accordingly, a significant number will not be cured by tumor surgical resection alone. Adjunctive radiation therapy cannot always offer biochemical and clinical disease control and carries a 40% risk of partial or total pituitary failure in the medium term. Several monotherapies or combination medical therapies are currently available for both primary and adjuvant acromegaly treatment, and include long-acting somatostatin analogs, the growth hormone receptor antagonist pegvisomant, and dopamine agonists. Next generation somatostatin analogs and new drug delivery methods of existing agents are in ongoing clinical studies. This paper will review current and novel therapies under development for acromegaly.

Keywords: acromegaly, growth hormone, pituitary tumors, somatostatin analog, pasireotide, pegvisomant

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Medical treatment of Cushing's disease: Overview and recent findings

Stephanie Smooke Praw, Anthony P Heaney

International Journal of General Medicine 2009, 2:209-217

Published Date: 21 October 2009

Readers of this article also read:

Accuracy and precision of cap thickness in small incision lenticule extraction

Ozgurhan EB, Agca A, Bozkurt E, Gencer B, Celik U, Cankaya KI, Demirok A, Yilmaz OF

Clinical Ophthalmology 2013, 7:923-926

Published Date: 21 May 2013

Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo

Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F, Wang X

International Journal of Nanomedicine 2013, 8:1867-1877

Published Date: 9 May 2013

Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation

Chen Y, Sha X, Zhang W, Zhong W, Fan Z, Ren Q, Chen L, Fang X

International Journal of Nanomedicine 2013, 8:1463-1476

Published Date: 16 April 2013

Facile one-step coating approach to magnetic submicron particles with poly(ethylene glycol) coats and abundant accessible carboxyl groups

Long GB, Yang XL, Zhang Y, Pu J, Liu L, Liu HB, Li YL, Liao F

International Journal of Nanomedicine 2013, 8:791-807

Published Date: 25 February 2013

Deposit buildup on prosthetic eye material (in vitro) and its effect on surface wettability

Pine KR, Sloan B, Han KYI, Swift S, Jacobs RJ

Clinical Ophthalmology 2013, 7:313-319

Published Date: 13 February 2013

Comparison of different intraocular pressure measurement techniques in normal eyes, post surface and post lamellar refractive surgery

Shousha SM, Abo Steit MA, Hosny MH, Ewais WA, Shalaby AM

Clinical Ophthalmology 2013, 7:71-79

Published Date: 8 January 2013

Validity and reproducibility of a physical activity questionnaire for older adults: questionnaire versus accelerometer for assessing physical activity in older adults

Siebeling L, Wiebers S, Beem L, Puhan MA, ter Riet G

Clinical Epidemiology 2012, 4:171-180

Published Date: 16 July 2012

In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy

Puvanakrishnan P, Park J, Chatterjee D, Krishnan S, Tunnell JW

International Journal of Nanomedicine 2012, 7:1251-1258

Published Date: 6 March 2012

Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients

Olga Khoudoleeva, Eugeny Gretsov, Natasha Barteneva, et al

Pathology and Laboratory Medicine International 2011, 3:7-16

Published Date: 28 January 2011